Atlas Trials

Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

Clinical trial NCT04920747 · COMPLETED

Trial details

NCT number
NCT04920747
Sponsor
Centre Hospitalier Universitaire de Besancon
Status
COMPLETED
Study type
OBSERVATIONAL
HER2-positive Gastric CancerMetastatic CancerDocetaxelTrastuzumab
Start date
2021-04-01
Primary completion
2021-05-31
Enrollment
65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.